Form 4: Reprogrammed Interchange Sells VOR Shares

Reprogrammed Interchange LLC, a 10% owner and director, reported the sale of 447,278 shares of Vor Biopharma Inc. common stock for $1.5401 per share.

Summary

• Reprogrammed Interchange LLC, a 10% owner and director of Vor Biopharma Inc. (VOR), sold 447,278 shares of common stock.
• The transaction occurred on September 16, 2025, at a weighted average price of $1.5401 per share, with individual trades ranging from $1.52 to $1.58.
• Following the sale, Reprogrammed Interchange LLC beneficially owns 32,781,209 shares of Vor Biopharma Inc. common stock.
• The sale was executed pursuant to a Rule 10b5-1 trading plan, indicating it was pre-arranged.
• Reid Hoffman, associated with Reprogrammed Interchange LLC, disclaims beneficial ownership of the securities held by Reprogrammed, except to the extent of his pecuniary interest therein.

Sentiment

Score: 4

Explanation: The sale of a significant block of shares by a 10% owner and director, Reprogrammed Interchange LLC, could be perceived as a negative signal by the market. However, the transaction was executed under a Rule 10b5-1 plan, which suggests it was pre-scheduled and not necessarily based on new, adverse material information, mitigating some of the negative sentiment.

Negatives

• A 10% owner and director, Reprogrammed Interchange LLC, sold a substantial block of 447,278 shares.
• Insider selling, especially by a significant owner, can sometimes be interpreted negatively by the market, potentially signaling a lack of confidence or a need for liquidity.

Management Comments

• The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
• Mr. Hoffman disclaims beneficial ownership of the securities held by Reprogrammed, except to the extent of his pecuniary interest therein.

Related Party Transactions

• Reprogrammed Interchange LLC, a 10% owner and director of Vor Biopharma Inc., sold 447,278 shares of common stock, which constitutes an insider transaction.

Stakeholder Impact

• Shareholders: The sale by a significant insider could lead to negative market sentiment, potentially impacting share price.

Key Dates

Recommendation

The sale of shares by a 10% owner and director, Reprogrammed Interchange LLC, while notable, was conducted under a Rule 10b5-1 plan, indicating a pre-scheduled transaction rather than an immediate reaction to new company developments. While insider selling can sometimes be a negative signal, this specific transaction alone does not provide sufficient grounds for a 'sell' recommendation without further analysis of the company's fundamentals, future prospects, and broader market conditions. Therefore, a 'hold' recommendation is appropriate, advising investors to monitor future filings and company performance.

Keywords

Vor Biopharma, VOR, Reprogrammed Interchange LLC, Reid Hoffman, Insider Sale, Form 4, Beneficial Ownership, Common Stock, Director, 10% Owner, Rule 10b5-1